BRIEF—Positive data for Biocad's plaque psoriasis therapy

Saint Petersburg-based BIOCAD has presented positive Phase III data from the PLANETA study of netakimab in patients with moderate to severe plaque psoriasis.

The firm is testing the IL-17 inhibitor in people who have failed to respond to conventional therapies, including previous treatment with other biologics.

The study met its primary endpoint, with 83.3% of subjects in the netakimab group showing a 75% improvement according to a commonly-used scale.

BIOCAD expects netakimab to be launched onto the Russian market in 2019. The company plans also to apply for marketing authorization in the EU and in China.